RT Journal Article SR Electronic T1 Genome-wide analyses in 1,987,836 participants identify 39 genetic loci associated with sleep apnoea JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.09.29.20199893 DO 10.1101/2020.09.29.20199893 A1 Adrian I. Campos A1 Nathan Ingold A1 Yunru Huang A1 Pik-Fang Kho A1 Xikun Han A1 Jue-Sheng Ong A1 Luis M. García-Marín A1 23andMe Research Team A1 Matthew H. Law A1 Nicholas G. Martin A1 Xianjun Dong A1 Gabriel Cuellar-Partida A1 Stuart MacGregor A1 Stella Aslibekyan A1 Miguel E. Rentería YR 2020 UL http://medrxiv.org/content/early/2020/09/30/2020.09.29.20199893.abstract AB Rationale Sleep apnoea is a complex disorder characterised by periods of halted breathing during sleep. Despite its association with serious health conditions such as cardiovascular disease, the aetiology of sleep apnoea remains understudied, and previous genetic studies have failed to identify replicable genetic risk factors.Objective To advance our understanding of factors that increase susceptibility to sleep apnoea by identifying novel genetic associations.Methods We conducted a genome-wide association study (GWAS) meta-analysis of sleep apnoea across five cohorts, and a previously published GWAS of apnoea-hypopnea index (NTotal=510,484). Further, we used multi-trait analysis of GWAS (MTAG) to boost statistical power, leveraging the high genetic correlations between apnoea, snoring and body mass index. Replication was performed in an independent sample from 23andMe, Inc (NTotal=1,477,352; Ncases=175,522)Measurements and Main Results Our results revealed 39 independent genomic loci robustly associated with sleep apnoea risk, and significant genetic correlations with multisite chronic pain, sleep disorders, diabetes, high blood pressure, osteoarthritis, asthma and BMI-related traits. We also derived polygenic risk scores for sleep apnoea in a leave-one-out independent cohort and predicted probable sleep apnoea in participants (OR=1.15 to 1.22; variance explained = 0.4 to 0.9%).Conclusions We report novel genetic markers robustly associated with sleep apnoea risk and substantial molecular overlap with other complex traits, thus advancing our understanding of the underlying biological mechanisms of susceptibility to sleep apnoea.Competing Interest StatementStella Aslibekyan, Yunru Huang, and Gabriel Cuellar-Partida are current or former employees of 23andMe, Inc. and may hold stock or stock options. All other authors declare no conflicts of interest.Funding StatementFunding for the Canadian Longitudinal Study on Aging (CLSA) is provided by the Government of Canada through the Canadian Institutes of Health Research (CIHR) under grant reference: LSA 94473 and the Canada Foundation for Innovation. This research has been conducted using the CLSA dataset [Baseline Comprehensive Dataset version 4.0, Follow-up 1 Comprehensive Dataset version 1.0], under Application Number 190225.Data collection for the Australian Genetics of Depression Study was possible, thanks to funding from the Australian National Health & Medical Research Council (NHMRC) to N.G.M. (GNT1086683).A.I.C. is supported by UQ Research Training Scholarships from The University of Queensland (UQ). P.F.K. is supported by an Australian Government Research Training Program Scholarship from Queensland University of Technology (QUT). M.E.R. thanks support of the NHMRC and Australian Research Council (GNT1102821). SM is supported by a research fellowship from the Australian National Health and Medical Research Council (NHMRC). This work was supported by an NHMRC project grant [1123248].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the QIMR Berghofer Human Research Ethics Committee. In addition, relevant details for each of the participating cohorts are provided below:The UK Biobank study was approved by the National Health Service National Research Ethics Service (ref. 11/NW/0382) and all participants provided written informed consent to participate in the UK Biobank study. Information about ethics oversight in the UK Biobank can be found at https://www.ukbiobank.ac.uk/ethics/.Participants in the AGDS provided informed consent prior to participating in the study. All questionnaires used for AGDS were approved by the QIMR Berghofer Human Research Ethics Committee.Participants in the Partners Healthcare Biobank provided informed consent at sign up and ethics approval was obtained from the Partners Human Research Committee.The Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District has evaluated and approved the FinnGen project.The protocol of the CLSA has been reviewed and approved by 13 research ethics boards across Canada.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full GWAS summary statistics for this study will be made available through the NHGRI-EBI GWAS Catalogue (https://www.ebi.ac.uk/gwas/downloads/summary-statistics). Data are available from the Canadian Longitudinal Study on Aging (www.clsa-elcv.ca) for researchers who meet the criteria for access to de-identified CLSA data. UK Biobank and FinnGen data are also accessible through their respective application procedures.